Williams also addressed CMS’s Medicare Advantage (MA) Advance Notice for 2027, saying the proposal “does not sufficiently reflect” rising costs and utilization from chronic disease and an aging Medicare population. He said the company expects the impact of the risk model revision and normalization described in the Advance Notice to be “generally in line with the national average,” and argued that agilon’s burden of illness and clinical pathway programs can help mitigate risk model impacts, as they did durin ...